What is Aquestive Therapeutics 12-1 Month Momentum %?
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-28), Aquestive Therapeutics's 12-1 Month Momentum % is 224.80%.
The industry rank for Aquestive Therapeutics's 12-1 Month Momentum % or its related term are showing as below:
AQST's 12-1 Month Momentum % is ranked better than 98.47% of 1112
companies
in the Drug Manufacturers industry
Industry Median: -5.73
vs AQST: 224.80
Competitive Comparison of Aquestive Therapeutics's 12-1 Month Momentum %
For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aquestive Therapeutics's 12-1 Month Momentum % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Aquestive Therapeutics's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Aquestive Therapeutics 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Aquestive Therapeutics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Aquestive Therapeutics (Aquestive Therapeutics) Business Description
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AQST has been successfully added to your